Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 in Generalized Pustular Psoriasis or Erythrodermic Psoriasis
NCT06323356Phase 3Completed
- Sponsor
- Takeda
- Start
- Mar 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zasocitinib in generalized pustular psoriasis (GPP), erythrodermic psoriasis (EP), sponsored by Takeda. Started Mar 2024; status: completed.
02
Drugs
zasocitinib
03
Conditions
generalized pustular psoriasis (GPP)erythrodermic psoriasis (EP)
Beyond the preview
Go deeper on NCT06323356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06323356.